Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

IRIX - IRIDEX Corporation Последние новости | Finranks

Home

IRIX

I

IRIDEX Corporation (IRIX)

NCM – Цена в реальном времени. Валюта: USD

0.99

-0.36 (-26.67%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

1.02

+0.03 (3.03%)

После закрытия: Mar 27, 2026, 7:38 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026.

Iridex Announces Plans to Relocate Headquarters

Iridex Announces Plans to Relocate Headquarters

MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California.

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026.

Zacks Initiates Coverage of Iridex With Neutral Recommendation

Zacks Initiates Coverage of Iridex With Neutral Recommendation

Discover why Zacks initiated coverage of IRIX with a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Learn how global sales momentum and stronger liquidity are balanced against margin pressures and dependency on a key distributor.

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma.1

Видео

No Data

There is no data to display

Пресс-релизы

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies

Iridex Announces Plans to Relocate Headquarters

02.02.2026

Iridex Announces Plans to Relocate Headquarters

MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California.

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026.

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma.1